Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. OBJECTIVES: To study outcomes following opioid detoxification with ibogaine. METHODS: In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5 females) received a mean total dose of 1,540 ± 920 mg ibogaine HCl. Subjects used oxycodone (n = 21; 70%) and/or heroin (n = 18; 60%) in respective amounts of 250 ± 180 mg/day and 1.3 ± 0.94 g/day, and averaged 3.1 ± 2.6 previous episodes of treatment for opioid dependence. Detoxification and follow-up outcomes at 1, 3, 6, 9, and 12 months were evaluated utilizing the Subjective Opioid Withdrawal Scale (SOWS) and Addiction Severity Index Composite (ASIC) scores, respectively. RESULTS: SOWS scores decreased from 31.0 ± 11.6 pretreatment to 14.0 ± 9.8 at 76.5 ± 30 hours posttreatment (t = 7.07, df = 26, p < 0.001). At 1-month posttreatment follow-up, 15 subjects (50%) reported no opioid use during the previous 30 days. ASIC Drug Use and Legal and Family/Social Status scores were improved relative to pretreatment baseline at all posttreatment time points (p < .001). Improvement in Drug Use scores was maximal at 1 month, and subsequently sustained from 3 to 12 months at levels that did not reach equivalence to the effect at 1 month. CONCLUSION: Ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful, and may provide a useful prototype for discovery and development of innovative pharmacotherapy of addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Privileged scaffolds for library design and drug discovery
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509
Self-report among injecting drug users: A review
Darke, S. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00028-3 · Cited by 1,141 · cited 1×
“Nonetheless, self-reporting in clinical research on SUDs is often accurate (80), particularly when there are no negative consequences to the subject for reporting use.”
BackgroundWeiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540 · cited 1×
“of ≤4 days of opioid use in the previous 30 days, at 8 weeks subsequent to tapering and discontinuing buprenorphine with no subsequent pharmacotherapy (68).”
BackgroundGood Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul, S., & Diamond, G. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00011 · Cited by 272 · cited 1×
“This question was addressed with noninferiority tests (66,67) on the 20 subjects available for follow-up at 1 month.”
MethodDiscontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Maisonneuve, I. M., Keller, R. W., & Glick, S. D. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90634-3 · Cited by 126
Glick, S. D., Maisonneuve, I. M., Kitchen, B. A., & Fleck, M. W. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01284-0 · Cited by 122 · cited 1×
“receptor (nAChR) is suggested to mediate its effect on drug self-administration (55), but does not appear to readily explain the prolonged effects that appear to”
Background(2001) · The Alkaloids: Chemistry and Biology · doi:10.1016/s0099-9598(01)56006-x · Cited by 64
Cited by
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Metadata
- Authors
- Brown, T. K., & Alper, K.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2017-05-25
- Volume
- 44
- Issue
- 1
- Pages
- 24-36
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- OpenAlex
- W2618371434
- Cited by
- 159
- References
- 8
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. https://app.cochat.ai/papers/10.1080/00952990.2017.1320802
- The paper
- Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2017.1320802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.